Renal Effects of Anti-angiogenesis Therapy: Update for the Internist

American Journal of Medicine

Volumn 122, Issue 4, 2009, Pages 322-328

  Gurevich, Faina ^a   Perazella, Mark A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti angiogenesis therapy; Hypertension; Kidney injury; Proteinuria; Thrombotic microangiopathy; Vascular endothelial growth factor (VEGF)

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; AXITINIB; BEVACIZUMAB; FLUOROURACIL; NITRIC OXIDE; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR; VATALANIB;

ACUTE KIDNEY FAILURE; ALOPECIA; ANEMIA; ANGIOGENESIS; ANOREXIA; BLEEDING; BONE MARROW SUPPRESSION; COLORECTAL CANCER; CONSTIPATION; CRYOGLOBULINEMIA; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFECT; DRY SKIN; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GLOMERULOPATHY; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HISTOPATHOLOGY; HUMAN; HYPERAMYLASEMIA; HYPERTENSION; HYPOTHYROIDISM; INTERSTITIAL NEPHRITIS; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY FUNCTION; KIDNEY INJURY; LEUKOPENIA; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; METASTASIS; MUCOSAL BLEEDING; NAUSEA; NEPHROTIC SYNDROME; OXIDATIVE STRESS; PAIN; PATHOGENESIS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISCOLORATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR GROWTH; VOMITING; WEIGHT REDUCTION; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; HUMANS; KIDNEY DISEASES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 63049088767     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.11.025     Document Type: Review

References (43)

1. Folkman J. Tumor angiogenesis. Therapeutic implications. N Engl J Med 285 (1971) 1182-1186
2. Izzedine H., Rixe O., Billemont B., et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 50 2 (2007) 203-218
3. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77 (1999) 527-543
4. Maharaj A.S.R., Saint-Geniez M., Maldonado A.E., and D'Amore P. Vascular endothelial growth factor localization in the adult. Am J Pathol 168 2 (2006) 639-648
5. Esser S., Wolburg K., Wolburg H., et al. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 140 4 (1998) 947-959
6. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist 5 Suppl 1 (2000) 20-27
7. Gerber D.E. Targeted therapies: a new generation of cancer treatments. Am Fam Physician 77 3 (2008) 311-319
8. Lin Y.S., Nguyen C., Mendoza J.L., et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288 1 (1999) 371-378
9. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676
10. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
11. Yang J.C., Haworth L., Sherry R., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
12. Sandler A., Gray R., Perry M., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006) 2542-2550
13. Emmanouilides C., Sfakiotaki G., Androulakis N., et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer 7 (2007) 91
14. Rudge J.S., Holash J., Hylton D., et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 104 47 (2007) 18363-18370
15. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 2 (2007) 115-124
16. Escudier B., Eisen T., Stadler W.M., et al., TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 2 (2007) 125-134
17. Lameire N.H., Flombaum C.D., Moreau D., and Ronco C. Acute renal failure in cancer patients. Ann Med 37 1 (2005) 13-25
18. Hurwitz H., Fehrenbacher L., Cartwright T., et al. Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab. J Clin Oncol 22 14S (2004) 3702 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
19. Veronese M.L., Mosenkis A., Flaherty K.T., et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24 (2006) 1363-1369
20. Zhu X., Wu S., Dahut W., et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49 (2007) 186-193
21. Zhu X., Stergiopoulos K., and Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 27 (2008) 1-9
22. Wu S., Chen J.J., Kudelka A., Lu J., and Zhu X. Incidence and risk of hypertension with sorafenib in cancer patients. Lancet Oncol 9 (2008) 117-123
23. Hood J.D., Meininger C.J., Ziche M., et al. VEGF upregulates eNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274 (1998) H1054-H1058
24. Shen B.Q., Lee D.Y., and Zioncheck T.F. Vascular endothelial growth factor governs nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 274 (1999) 33057-33063
25. Zou A.P., and Cowley A.W. Role of nitric oxide in the control of renal function and salt sensitivity. Curr Hypertens Rep 1 2 (1999) 178-186
26. Feihl F., Liaudet L., Waeber B., and Levy B.I. Hypertension. A disease of the microcirculation?. Hypertension 48 (2006) 1012-1017
27. Struyker-Boudier H.A., le Noble J.L., Slaaf D.W., et al. Microcirculatory changes in cremaster muscle during early spontaneous hypertension in the rat. J Hypertens Suppl 6 4 (1988) S185-S187
28. Harper R.N., Moore M.A., Marr M.C., et al. Arteriolar rarefaction in the conjunctiva of human essential hypertensives. Microvasc Res 16 (1978) 369-372
29. Castilla M.A., Caramelo C., Gazapo R.M., et al. Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents. Life Sci 67 (2000) 1003-1013
30. 2. Am J Physiol Heart Circ Physiol 291 (2006) H1395-H1401
31. Pande A., Lombardo J., Spangenthal E., and Javle M. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res 27 5B (2007) 3465-3470
32. Patel T.V., Morgan J.A., Demetri G.D., et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 100 4 (2008) 282-284
33. Sugimoto H., Hamano Y., Charytan D., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278 15 (2003) 12605-12608
34. Kamba T., and McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96 (2007) 1788-1795
35. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
36. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
37. George B.A., Zhou X.J., and Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 49 (2007) 23-29
38. Eremina V., Jefferson A., Kowalewska J., et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358 (2008) 1129-1136
39. Izzedine H., Rixe O., Brocheriou I., and Deray G. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 22 (2007) 1481-1482
40. Roncone D., Satoskar A., Nadasdy T., Monk J.P., and Rovin B.H. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol 3 (2007) 287-293
41. Frangie C., Lefaucheur C., Medioni J., et al. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 8 2 (2007) 177-178
42. Hara A., Wada T., Furuichi K., et al. Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int 69 11 (2006) 1986-1995
43. Barakat R.K., Singh N., Lal R., et al. Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma. Ann Pharmacother 41 4 (2007) 707-710